AU2021250462A1 - Methods and compositions for treating or preventing an inflammatory condition - Google Patents

Methods and compositions for treating or preventing an inflammatory condition Download PDF

Info

Publication number
AU2021250462A1
AU2021250462A1 AU2021250462A AU2021250462A AU2021250462A1 AU 2021250462 A1 AU2021250462 A1 AU 2021250462A1 AU 2021250462 A AU2021250462 A AU 2021250462A AU 2021250462 A AU2021250462 A AU 2021250462A AU 2021250462 A1 AU2021250462 A1 AU 2021250462A1
Authority
AU
Australia
Prior art keywords
cbd
hydroxychloroquine
pharmaceutically acceptable
inflammatory
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021250462A
Other languages
English (en)
Inventor
Sudhanshu Agarwal
Mark Robert BLEACKLEY
Joel Bradley LATHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incannex Healthcare Ltd
Original Assignee
Incannex Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901030A external-priority patent/AU2020901030A0/en
Application filed by Incannex Healthcare Ltd filed Critical Incannex Healthcare Ltd
Publication of AU2021250462A1 publication Critical patent/AU2021250462A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021250462A 2020-04-02 2021-03-15 Methods and compositions for treating or preventing an inflammatory condition Pending AU2021250462A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
AU2020901030A AU2020901030A0 (en) 2020-04-02 A method of treatment
AU2020901030 2020-04-02
AU2020902432A AU2020902432A0 (en) 2020-07-14 A method of treatment
AU2020902432 2020-07-14
AU2020903985 2020-11-02
AU2020903985A AU2020903985A0 (en) 2020-11-02 A method of treatment
AU2020904264 2020-11-18
AU2020904264A AU2020904264A0 (en) 2020-11-18 A method of treatment
AU2021900241A AU2021900241A0 (en) 2021-02-03 A method of treatment
AU2021900241 2021-02-03
AU2021900324 2021-02-10
AU2021900324A AU2021900324A0 (en) 2021-02-10 A method of treatment
PCT/AU2021/050226 WO2021195691A1 (en) 2020-04-02 2021-03-15 Methods and compositions for treating or preventing an inflammatory condition

Publications (1)

Publication Number Publication Date
AU2021250462A1 true AU2021250462A1 (en) 2022-12-01

Family

ID=77926837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021250462A Pending AU2021250462A1 (en) 2020-04-02 2021-03-15 Methods and compositions for treating or preventing an inflammatory condition

Country Status (8)

Country Link
US (1) US20230128114A1 (https=)
EP (1) EP4125835A4 (https=)
JP (1) JP2023521634A (https=)
AU (1) AU2021250462A1 (https=)
CA (1) CA3169702A1 (https=)
CO (1) CO2022015048A2 (https=)
IL (1) IL296943A (https=)
WO (1) WO2021195691A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325312A1 (en) * 2021-07-15 2024-10-03 Incannex Healthcare Limited Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule
WO2024025525A1 (en) * 2022-07-27 2024-02-01 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
GB9807639D0 (en) * 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
US20040242632A1 (en) * 2001-11-09 2004-12-02 Charous B. Lauren Method for treating inflammatory bowel disease
US20200009077A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Compositions for treating dermatological diseases
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途

Also Published As

Publication number Publication date
WO2021195691A1 (en) 2021-10-07
IL296943A (en) 2022-12-01
EP4125835A4 (en) 2024-05-22
JP2023521634A (ja) 2023-05-25
EP4125835A1 (en) 2023-02-08
CO2022015048A2 (es) 2022-11-08
US20230128114A1 (en) 2023-04-27
CA3169702A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
Liu et al. Discovery of a novel rice-derived peptide with significant anti-gout potency
Amo-Aparicio et al. Inhibition of the NLRP3 inflammasome by OLT1177 induces functional protection and myelin preservation after spinal cord injury
US20230128114A1 (en) Methods and compositions for treating or preventing an inflammatory condition
EP3958855A2 (en) Methods for reducing the weight loss or increasing the weight of a feline in need thereof
Zhang et al. A phytomedicine extract exerts an anti-inflammatory response in the lungs by reducing STING-mediated type I interferon release
EA026713B1 (ru) Твердая пероральная лекарственная форма для лечения дефицита железа или анемии и ее применение
US20240325312A1 (en) Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule
Chen et al. Pterostilbene attenuates intrauterine growth retardation-induced colon inflammation in piglets by modulating endoplasmic reticulum stress and autophagy
CN117396197A (zh) 慢性肾脏病的猫的治疗方法
US20170105979A1 (en) Use of a torasemide-based veterinary composition for low-dose administering
JP7337389B2 (ja) ヒアルロン酸を有効成分として含むアレルゲン作用増強剤
WO2021006941A1 (en) Telmisartan for the treatment of chronic kidney disease in dogs
TWI899523B (zh) 使用生長因子來治療關節炎
TWI789123B (zh) 使用生長因子來治療關節炎
WO2011040052A1 (ja) アトピー性皮膚炎の治療薬
EP4556472A1 (en) Use of pyridone derivative
US20240217946A1 (en) Antidepressant and anxiolytic substituted cinnamamide compound
RU2833560C1 (ru) Композиции, содержащие 15-hepe, для лечения или профилактики гематологических нарушений и/или связанных заболеваний
CN111032030B (zh) 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
Onah et al. Histopathological Alterations in Cutaneous Wound Healing and Pancreatic Architecture in Alloxan-Induced Diabetic Rabbits.
Liu et al. A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu-pGSN) Following Intravenous Administration to Healthy Volunteers
HK40077420A (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
US20200085898A1 (en) Cucumis sativus l. extract for use in the treatment and/or prevention of enteropathies, particularly of inflammatory origin, in pets, and feed containing such extract
TW202508624A (zh) Ｃｃｌ７拮抗劑在預防或治療糖尿病腎病變的應用
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療